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Abstract
Background: Sometimes, no definite filling defect could be found by cholangiogram (ERC) during the endoscopic
retrograde cholangio-pancreatiographic (ERCP) exam; even prior images had evidence of common bile duct stones
(CBDS). We aimed in estimating the positive rate of extraction of CBDS who had treated by endoscopic
sphincterotomy/endoscopic papillary balloon dilation (EST/EPBD) with negative ERC finding.
Methods: One hundred forty-one patients with clinically suspicious of CBDS but negative ERC, who had received
EST/EPBD treatments was enrolled. Potential factors for predicting CBDS, as well as the treatment-related
complications were analyzed.
Results: Nearly half of the patients with negative ERC, had a positive stone extraction. Only patients with high
probability of CBDS were significantly associated with positive stone extraction. Moreover, patients with intermediate
probability of CBDS had higher rates of overall complications, including post-ERCP pancreatitis. In addition, no
significant difference of post-ERCP pancreatitis was found between EST and EPBD groups in any one group of patients
with the same probability of CBDS.
Conclusions: Regarding patients with negative ERC, therapeutic ERCP is beneficial and safe for patients present with
high probability of CBDS. Moreover, under the same probability of CBDS, there was no significance difference in
post-ERCP pancreatitis between EST and EPBD.
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Background
Common bile duct stone (CBDS) is an important clinical
problem that can cause serious complications, such as
acute cholangitis and pancreatitis [1]. Therefore, it is
recommended to remove the stones endoscopically or
surgically once diagnosis is established [2]. However,
sometimes, early definitive diagnosis of choledocholithiasis
is difficult and should be based on clinical symptoms and
signs, biochemical data and image findings.
Persist elevation of serum alkaline phosphatase (ALP)
and alanine transaminase (ALT) were shown to correlate
with the presence of CBDS even with a normal-sized
CBD [3]. A recent study showed that trans-abdominal
ultrasound alone is inadequate to predict the CBDS in
patients presenting with acute cholecystitis [4].
Endoscopic retrograde cholangiopancreatography (ERCP)
is generally believed to be the gold standard for both
diagnosis and treatment of CBDS. However, inevitably,
the procedure is associated with an overall complica-
tion rate of 4 ~ 10 % and mortality rate of 0.02 ~ 0.5 %
[5–10]. The major complications include pancreatitis
(1.3 ~ 6.7 %), infection (0.3 ~ 5.0 %), hemorrhage (0.3 ~
2.0 %), and perforation (0.1 ~ 1.1 %) [6, 9, 11]. Others in-
clude cardiac (<0.1 %), and pulmonary events (<0.1 %) [6].
Therefore, currently, purely diagnostic ERCP is not
suggested [7, 8]. Instead, relative non-invasive imaging
modalities such as MRCP and EUS are preferred.
In 2010, the American Society for Gastrointestinal
Endoscopy (ASGE) established a general rule for the
evaluation of likelihood of choledocholithiasis, in which;
Patients were divided into “high probability (risk of
CBDS > 50 %)”, “intermediate probability (risk of CBDS:
10 ~ 50 %)”, and “low probability (risk of CBDS < 10 %)”
groups [12]. In addition, the author also pointed-out the
management algorithm for patients with symptomatic
choledocholithiasis [12]. However, sometimes, no obvious
filling defects inside CBD could be found by cholangio-
gram (ERC, Fig. 1), even prior images, such as trans-
abdominal ultrasound or CT scan, had demonstrated the
evidence of CBDS. Regarding the possible complications,
further the treatment procedures, such as endoscopic
sphincterotomy (EST) and/or papillary balloon dilation
(EPBD) in this situation is worthy consideration. The aim
of this retrospective study was to estimate the positive rate
of CBDS in patients with negative filling defects from
ERC, and the factors for possible CBDS prediction, as well
as the treatment-related complications (safety concern).
Methods
Study design, definition and patient selection
This retrospective study was approved by Institutional
Review Board of Kaohsiung Veterans General Hospital.
Eligibility of patients includes those who were clinically
classified as either intermediate or high risks for CBDS
Fig. 1 A female patient presented with epigastric pain, jaundice, while CT scan showing dilated CBD and suspicious of CBDS. In addition, no
definite filling defect was found by ERC. However, EPBD was performed and a 1-cm hard stone was extracted subsequently
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[12] according to symptoms and signs, laboratory data
or image studies during the period of April 2008 to
March 2014. These patients had received either EST or
EPBD treatments, although no obvious filling defect was
detected by ERC. Exclusion criteria include peri-ampullary
tumors, hepatocellular disease, hemolytic disease, and pa-
tients who ever received endoscopic or surgical treatment
for bile duct stones. In addition, positive extraction of
stones was defined as stones detectable by naked eyes
through the video endoscopic pictures during extracting
the bile duct by using basket or balloon catheter; or pres-
ence of microlithiasis (non-visible by naked eyes) under
microscopic exams of the bile. The model of “probability
of CBDS” from American society for gastrointestinal en-
doscopy (ASGE, 2010) was applied in this study, in which
high probability of CBDS includes: 1) CBDS seen on
trans-abdominal ultrasonography (US) (and/or CT scan),
2) signs of acute cholangitis (people who had Charcot’s
triad), 3) total bilirubin > 4 mg/dL, 4) both dilated CBD on
US (>6 mm with gallbladder in situ and > 10 mm with
cholecystectomy) and total bilirubin level 1.8 ~ 4 mg/dL;
and intermediate probability of CBDS includes: 1) either
one of these two factors: dilated CBD on US or total bili-
rubin level 1.8 ~ 4 mg/dL, 2) advanced age (>55 year-old),
3) elevation of a liver biochemical test other than bilirubin,
and 4) gallstone pancreatitis. In addition, ERCP-related
complications were defined and graded in severity accord-
ing to the consensus criteria, which was adapted as
(Table 1), developed by Cotton et al. [6, 7, 11].
Endoscopic Procedures
Patients were conscious for the procedure and received
10 % xylocaine spray for local anesthesia of the pharynx,
intramuscular injection with 40 mg hyoscine-N-butyl-
bromide, and intramuscular injection with 25–50 mg
meperidine. ERCP was performed in the standard manner
using a side-view endoscope (JF-240; Olympus Optical
Corporation, Tokyo, Japan). After selective cannulation of
the common bile duct by the catheter, cholangiography
was performed to evaluate the presence/absence of
filling defects inside CBD. A 0.035-in. guide wire was
then inserted into the bile duct through the catheter.
For EST group, sphincterotomy was done by using a
wire-guided sphincterotome. Incision was started at
the orifice of papilla and extended upward to the dir-
ection of bile duct. For EBPD, selective cannulation of
the common bile duct with guide wire insertion was
the same as EST. A dilating balloon (CRE balloon;
Boston Scientific, Corp, Ireland) was passed via the
prepositioned 0.035-in. guide wire into the bile duct.
Using fluoroscopic (AXIOM, Iconos R200, Siemens
AG 2002) and endoscopic guidance, the balloon was
inflated with sterile saline solution up to the optimal
size (at least > 6 mm in diameter) and duration (from
1.5 to 5 min) according to the patients’ condition and
tolerance. In order to minimize the risk of perforation,
the size of the balloon should be not exceed the size of
the CBD. After the balloon and guide wire were removed,
the CBDS was retrieved out using a Dormia basket or
balloon-tipped catheter with or without the aid of mech-
anical lithotripsy (BML-4Q; Olympus Optical, Tokyo,
Japan). Unnecessary cannulation or contrast injection of
pancreatic duct was avoided.
Statistical analysis
All statistical analyses were performed using the PASW
20.0 (IBM, New York, NY, USA). Continuous valuables
are expressed as mean ± SD. Chi-square analyses or Fish-
er’s exact tests were used for comparing categorical vari-
ables, while independent t-tests were used for comparing
Table 1 Consensus criteria for ERCP complicationsab
Mild Moderate Severe
Bleeding Clinical evidence of bleeding (ie, not just
endoscopic); Hb level drop <3 g; no need
for transfusion.
Transfusion: ≤4 units; no
angiographic intervention or surgery.
Transfusion: ≥5 units or intervention
(angiographic or surgical).
Perforation Possible, or only very slight leak of fluid or
contrast dye; treatable by fluids and suction
for ≤3 days.
Any definite perforation treated
medically for 4–10 days.
Medical treatment for more than 10 days
or intervention (percutaneous or surgical).
Pancreatitis Clinical pancreatitis; amylase at least 3 times
normal at more than 24 hours after the
procedure requiring admission or prolongation
of planned admission to 2–3 days.
Pancreatitis requiring hospitalization
of 4–10 days.
Pancreatitis requiring hospitalization for more
than 10 days, or hemorrhagic pancreatitis,
phlegmon or pseudocyst, or intervention
(percutaneous drainage or surgery).
Infection
(cholangitis)
>38°C at 24–48 hours. Febrile or septic illness requiring >3
days of hospital treatment or
endoscopic or percutaneous
intervention
Septic shock or surgery.
ie, mild, unplanned hospital stay of 2–3 nights; moderate, 4–10 nights; and severe (>10 nights or intensive care or surgery)
aFrom Ref. 6 and 11. ERCP, endoscopic retrograde cholangiopancreatography
bAll other complications were graded for severity of the need for hospitalization and/or surgical treatment
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continuous variables between patients with final positive
and negative stone extraction. Associations between the
possible predictors and the positivity of CBD stones and
between the possible predictors and complications were
assessed by multiple logistic regressions. Results were
shown as odds ratios and 95 % confidence intervals
(CIs). A p-value less than 0.05 was considered statistically
significant.
Results
Demographic data was shown in Table 2. No significant
difference was found at gender, age, body mass index
(BMI), initial GPT and ALP level, history of cholecystec-
tomy, presence/absence of gallbladder stones, and juxta-
papillary diverticulum (JPD), between patients with final
positive or negative stone extraction. There were only ini-
tial cholangitis and high probability of CBDS significantly
associated with positive stone extraction. There were total
141 (male/female: 81/60) patients, clinically suspicious of
CBD stones (intermediate probability: 28, high probability:
113), undergoing successful therapeutic ERCP (EST/
EPBD: 30/111) with which pre-treatment cholangiogram
(ERC) showed no obvious filling defects. For the group of
positive stone extraction (70 patients), there were 64 pa-
tients showed detectable (all are barely visible by naked
eyes and un-measurable) stones and six patients showed
microlithiasis under microscopic analysis of bile. However,
there were only 21 samples of bile available for analysis
(21/141 = 14.9 %). With regard to the high probability
group of CBDS, 65 cases presented with evidence of
CBDS at initial image, 25 with acute cholangitis, 10
with total bilirubin level >4 mg/dL, and 13 with mild
elevated total bilirubin (1.8–4 mg/dL) and CBDdilata-
tion. On the other hand, in the intermediate probability
group, 16 cases presented with mild elevated total bili-
rubin (1.8–4 mg/dL) without CBD dilatation, six with
CBD dilatation without elevated total bilirubin, two
with gallstone pancreatitis, and four with age > 55 year-
old. Besides, the mean length of EST was 0.91 cm
(0.5 cm ~ 1.5 cm); and the mean size of dilating balloon
was 0.99 cm (0.6 cm ~ 1.8 cm), depend on the relative
sizes of CBD. ERCP was performed at a mean of four
days after admission.
By using multiple logistic regressions, only high prob-
ability of CBDS was found to be significantly associated
with positive stone extraction (high vs. intermediate
probability: 54.9 % vs. 28.6 %, p = 0.039) (Table 3). More-
over, there were totally 11 (7.8 %) complications found
in the study (Table 4). By using multiple logistic regres-
sions, intermediate probability of CBDS was associated
with higher risk of overall complications and post-ERCP
pancreatitis (p = 0.043; p = 0.007) (Tables 4 and 5). In
addition, no significant difference in overall complications,
Table 2 Demographic data between groups with and without
stone extraction
Characteristics Stone (+) Stone (−) P-value
(n = 70) (n = 71)
Gender (Male/Female) 40/30 41/30 0.942
Age 66.73 ± 17.93 61.63 ± 15.55 0.073
BMI 24.54 ± 3.58 24.77 ± 3.95 0.736
Cholecystectomy 8 (11.4 %) 8 (11.3 %) 0.976
GB stone 54 (77.1 %) 54 (76.1 %) 0.879
JPD 31 (44.3 %) 26 (36.6 %) 0.354
ALT at admission 278.9 ± 282.8 283.7 ± 260.1 0.917
Alk-P at admission 175.1 ± 120.7 162.5 ± 149.7 0.590
Total bilirubin at admission 3.49 ± 2.37 3.35 ± 2.20 0.726
CBDS risk (high vs. intermediate) 62 (88.6 %) 51 (71.8 %) 0.013*
Cholangitis 29 (41.4 %) 14 (19.7 %) 0.005*
Pancreatitis 26 (37.1 %) 22 (31.0 %) 0.440
Abbreviations: BMI body mass index, GB gallbladder, JPD juxta-papillary
diverticulum, ALT aspartate transaminase, Alk-P alkaline phosphatase;
CBDS, common bile duct stone
*p < 0.05
Table 3 Risk factors of patients with stone extraction
Characteristics Complication (+) Complication (−) P-value OR 95 % CI of OR
(n = 70) (n = 71)
CBDS probability from ASGE
CBDS risk (high vs. intermediate) 62 (88.6 %) 51 (71.8 %) 0.039* 2.670 1.050 ~ 6.790
Characteristics
Gender (M/F) 40/30 41/30 0.992 1.004 0.496 ~ 2.031
BMI 24.54 ± 3.58 24.77 ± 3.95 0.540 0.971 0.883 ~ 1.067
Cholecystectomy 8 (11.4 %) 8 (11.3 %) 0.634 1.430 0.329 ~ 6.225
GB stone 54 (77.1 %) 54 (76.1 %) 0.504 1.453 0.486 ~ 4.349
JPD 31 (44.3 %) 26 (36.6 %) 0.212 1.593 0.767 ~ 3.310
Abbreviation: OR odd’s ratio
*p < 0.05
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including post-ERCP pancreatitis, was found between EST
and EPBD groups under the same probability of CBDS, no
matter high or intermediate probability. There were three
(mild/moderate/severe: 1/1/1) and four (mild/moderate/
severe: 1/3/0) post-ERCP pancreatitis found in EST and
EPBD groups, respectively. Moreover, two mild cholangitis
combined with moderate pancreatitis and two pure chol-
angitis (mild/moderate/severe: 1/0/1) were found in EPBD
group. However, no procedure-related mortality was noted
in the current study.
Discussion
According to the current study, nearly half (49.6 %) of
patients without detected filling defects in ERC, have
evidence of positive stone extraction after EST or EPBD
treatments. By multiple logistic regressions, only high
probability of CBDS was significantly associated with
positive stone extraction.
Total complication rate among patients received EST
or EPBD with negative filling defects from ERC was
7.80 %, and no significant difference was found between
these two treatment modalities. In addition, there was
no procedure-related mortality. Furthermore, intermediate
probability of CBDS was associated with higher risk of
overall complications, including post-ERCP pancrea-
titis. Therefore, endoscopic treatment (EST or EPBD) is
beneficial and safe for patients with high probability of
CBDS. In addition, no significant difference in overall
complications, as well as post-ERCP pancreatitis, was
found between EST and EPBD groups under the same
probabilities of stones.
The lack of important roles of liver function tests, such
as GPT, ALP before ERCP in the current results, as in the
previous studies [13–16] might be due to the small sample
size.
Moreover, bile analysis was inadequately done in this
study (14.9 %). Therefore, prospective study with bile
analysis of microlithiasis is crucial to elucidate the true
rate of CBDS in patients with negative filling defects in
ERC. In addition, endoscopic ultrasound might be done
before EST and EPBD in order to minimize the ERCP-
associated complications and to quickly delineate the
presence of small stones or sludge in the CBD [5].
Conclusions
The probability of CBDS (high vs. intermediate probabil-
ity) could play a significant role in the estimation of
positive stone extraction before deciding the therapeutic
strategies, with the result in fewer overall complications,
including post-ERCP pancreatitis after the treatment
even though the negative filling defect on ERC. In addition,
endoscopic treatment (EST or EPBD) is beneficial and safe
to patients with high probability of CBDS. Moreover, under
the same probability scores, there was no significant differ-
ence in post-ERCP pancreatitis between EST and EPBD.
Future prospective study with bile analysis of microlithiasis
is important to elucidate the true rate of CBDS in patients
with negative filling defects in ERC.
Table 4 Risk factors of the patients with complication
Characteristics Complication (+) Complication (−) P-value OR 95 % CI of OR
(n = 11) (n = 130)
Procedure
EST/EPBD 3 (27.3 %) 27 (20.8 %) 0.909 0.919 0.215 ~ 3.920
CBDS probability from ASGE
CBDS risk (high vs. intermediate) 6 (54.5 %) 107 (82.3 %) 0.043* 0.262 0.072 ~ 0.958
Abbreviations: EST endoscopic sphincterotomy, EPBD endoscopic papillary balloon dilation
*p < 0.05





P-value OR 95 % CI of OR
(n = 7) (n = 134)
Procedure
EST/EPBD 3 (42.9 %) 27 (20.1 %) 0.442 0.523 0.100 ~ 2.735
CBDS probability from ASGE
CBDS risk (high vs. intermediate) 2 (28.6 %) 111 (82.8 %) 0.007* 0.093 0.017 ~ 0.523
*p < 0.01; correlation between procedure and CBDS probability from ASGE showed no significance
(p = 0.456)
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